Literature DB >> 31462569

Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).

Hinh Ly1, Yuying Liang2, Junjie Shao1, Qinfeng Huang1, Xiaoying Liu1, Da Di1, Mythili Dileepan1, Morgan Brisse1.   

Abstract

Several mammarenaviruses can cause deadly hemorrhagic fever infections in humans, with limited preventative and therapeutic measures available. Arenavirus cell entry is mediated by the viral glycoprotein (GP) complex, which consists of the stable signal peptide (SSP), the receptor-binding subunit GP1, and the transmembrane subunit GP2. The GP2 cytoplasmic tail (CT) is relatively conserved among arenaviruses and is known to interact with the SSP to regulate GP processing and membrane fusion, but its biological role in the context of an infectious virus has not been fully characterized. Using a Pichinde virus (PICV) GP expression vector and a PICV reverse genetics system, we systematically characterized the functional roles of 12 conserved residues within the GP2 CT in GP processing, trafficking, assembly, and fusion, as well as in viral replication. Except for P478A and K505A R508A, alanine substitutions at conserved residues abolished GP processing and membrane fusion in plasmid-transfected cells. Six invariant H and C residues and W503 are essential for viral replication, as evidenced by the fact that their mutant viruses could not be rescued. Both P480A and R482A mutant viruses were rescued, grew similarly to wild-type (WT) virus, and produced evidently processed GP1 and GP2 subunits in virus-infected cells, despite the fact that the same mutations abolished GP processing and membrane fusion in a plasmid-based protein expression system, illustrating the importance of using an infectious-virus system for analyzing viral glycoprotein function. In summary, our results demonstrate an essential biological role of the GP2 CT in arenavirus replication and suggest it as a potential novel target for developing antivirals and/or attenuated viral vaccine candidates.IMPORTANCE Several arenaviruses, such as Lassa virus (LASV), can cause severe and lethal hemorrhagic fever diseases with high mortality and morbidity, for which no FDA-approved vaccines or therapeutics are available. Viral entry is mediated by the arenavirus GP complex, which consists of the stable signal peptide (SSP), the receptor-binding subunit GP1, and the transmembrane subunit GP2. The cytoplasmic tail (CT) of GP2 is highly conserved among arenaviruses, but its functional role in viral replication is not completely understood. Using a reverse genetics system of a prototypic arenavirus, Pichinde virus (PICV), we show that the GP2 CT contains certain conserved residues that are essential for virus replication, implicating it as a potentially good target for developing antivirals and live-attenuated viral vaccines against deadly arenavirus pathogens.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Lassa virus; Pichinde virus; arenavirus; entry; envelope glycoprotein; protein processing; viral replication

Year:  2019        PMID: 31462569      PMCID: PMC6819926          DOI: 10.1128/JVI.01277-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion.

Authors:  Emily L Messina; Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

2.  Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion.

Authors:  Joanne York; Jack H Nunberg
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins.

Authors:  Bruno Eschli; Katharina Quirin; Alexander Wepf; Jacqueline Weber; Rolf Zinkernagel; Hans Hengartner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Restricted expression of viral glycoprotein in cells of persistently infected mice.

Authors:  M B Oldstone; M J Buchmeier
Journal:  Nature       Date:  1982-11-25       Impact factor: 49.962

5.  Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers.

Authors:  Shuiyun Lan; Lisa McLay Schelde; Jialong Wang; Naveen Kumar; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

Review 6.  Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.

Authors:  Lisa McLay; Aftab Ansari; Yuying Liang; Hinh Ly
Journal:  Antiviral Res       Date:  2012-12-20       Impact factor: 5.970

7.  Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses.

Authors:  Jonathan Abraham; Kevin D Corbett; Michael Farzan; Hyeryun Choe; Stephen C Harrison
Journal:  Nat Struct Mol Biol       Date:  2010-03-07       Impact factor: 15.369

8.  Arenavirus stable signal peptide is the keystone subunit for glycoprotein complex organization.

Authors:  Lydia H Bederka; Cyrille J Bonhomme; Emily L Ling; Michael J Buchmeier
Journal:  mBio       Date:  2014-10-28       Impact factor: 7.867

9.  Use of Favipiravir to Treat Lassa Virus Infection in Macaques.

Authors:  Kyle Rosenke; Heinz Feldmann; Jonna B Westover; Patrick William Hanley; Cynthia Martellaro; Friederike Feldmann; Greg Saturday; Jamie Lovaglio; Dana P Scott; Yousuke Furuta; Takashi Komeno; Brian B Gowen; David Safronetz
Journal:  Emerg Infect Dis       Date:  2018-09-17       Impact factor: 6.883

Review 10.  Envelope glycoprotein of arenaviruses.

Authors:  Dominique J Burri; Joel Ramos da Palma; Stefan Kunz; Antonella Pasquato
Journal:  Viruses       Date:  2012-10-17       Impact factor: 5.048

View more
  1 in total

Review 1.  Lassa virus glycoprotein complex review: insights into its unique fusion machinery.

Authors:  Hallie N Pennington; Jinwoo Lee
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.